통풍 환자의 혈청 호모시스테인 변화와 요신 및 지질, 신기능 변화의 연관성: 2년 추적 관찰 연구 = Two-year Follow-up Study of the Relationship between the Changes of Serum Homocysteine and Those of Serum Uric Acid Levels, Lipid Profiles and Renal Function in Gout Patients

다국어 초록 (Multilingual Abstract)

Objective. Gout is known to be associated with cardiovascular disease (CVD), and hyperhomocysteinemia is one of the risk factors for CVD. We investigated the associations between the change of serum homocysteine (Hcy) level and those of the other parameters including serum uric acid level, renal function, and cholesterol profiles in chronic gout patients with longitudinal follow-up data. Methods. Ninety-one male patients with chronic gout and 97 age-matched healthy male control subjects were included in the previous study. Among them, 33 patients with gout and 39 healthy control subjects underwent follow-up tests for Hcy levels with an average of 24.00±9.12 months in this study. Results. The follow-up data showed that gout patients had significantly higher levels of Hcy in serum than control subjects (16.75±5.43 μmol/L vs. 13.17±3.83 μmol/L, p=0.002). In gout patients, the change of serum Hcy level after follow up showed positive correlation with the change of creatinine (γ=0.442, p=0.009) and negative correlation with estimated glomerular filtration rate (eGFR; γ=.0.528, p＜0.001). However, the change of serum Hcy level did not show correlation with the changes of uric acid level or the lipid profiles. Conclusion. Serum Hcy level was elevated in gout patients compared with control subjects. The change of serum Hcy level showed negative correlation with the change of eGFR. Hyperhomocysteinemia in gout patients was associated with decreased renal function, but not with serum uric acid or lipid profiles. (J Rheum Dis 2016;23:30-36)

참고문헌 (Reference)

1 Hayden MR, "Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle" 1 : 10-, 2004

2 Feig DI, "Uric acid and cardiovascular risk" 359 : 1811-1821, 2008

3 Batuman V, "The role of lead in gout nephropathy" 304 : 520-523, 1981

4 Full LE, "The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus" 11 : 217-, 2009

5 Young Hee Rho, "The Prevalence of Metabolic Syndrome in Patients with Gout :A Multicenter Study" 대한의학회 20 (20): 1029-1033, 2005

6 Chen SY, "Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study" 26 : 308-313, 2007

7 Iso H, "Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese" 109 : 2766-2772, 2004

8 Bazzano LA, "Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States" 138 : 891-897, 2003

9 Rathmann W, "Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary artery risk development in young adults" 8 : 250-261, 1998

10 Choi HK, "Prevalence of the metabolic syndrome in patients with gout: the third National Health and Nutrition examination survey" 57 : 109-115, 2007

11 Wallace SL, "Preliminary criteria for the classification of the acute arthritis of primary gout" 20 : 895-900, 1977

12 Danesh J, "Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses" 321 : 199-204, 2000

13 Krishnan E, "Long-term cardiovascular mortality among middle-aged men with gout" 168 : 1104-1110, 2008

14 Lentz SR, "Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine" 88 : 1906-1914, 1991

15 Choi HK, "Independent impact of gout on mortality and risk for coronary heart disease" 116 : 894-900, 2007

16 Puig JG, "Hyperuricemia, gout and the metabolic syndrome" 20 : 187-191, 2008

17 Khosla UM, "Hyperuricemia induces endothelial dysfunction" 67 : 1739-1742, 2005

18 Avram Z, "Hyperuricaemia−where nephrology meets rheumatology" 47 : 960-964, 2008

19 van Guldener C, "Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation" 43 : 1026-1031, 2005

20 Hajjar KA, "Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor" 91 : 2873-2879, 1993

21 Slot O, "Homocysteine, a marker of cardiovascular disease risk, is markedly elevated in patients with gout" 72 : 457-, 2013

22 Kelly PJ, "Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis" 59 : 529-536, 2002

23 Majors A, "Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells" 17 : 2074-2081, 1997

24 McCully KS, "Homocysteine and vascular disease" 2 : 386-389, 1996

25 Kuo CF, "Gout: an independent risk factor for all-cause and cardiovascular mortality" 49 : 141-146, 2010

26 Abbott RD, "Gout and coronary heart disease: the Framingham study" 41 : 237-242, 1988

27 Cheng TT, "Elevated serum homocysteine levels for gouty patients" 24 : 103-106, 2005

28 최상태, "Elevated Serum Homocysteine Levels Were Not Correlated with Serum Uric Acid Levels, but with Decreased Renal Function in Gouty Patients" 대한의학회 29 (29): 788-792, 2014

29 Kang SS, "Critical points for determining moderate hyperhomocyst(e)inaemia" 25 : 806-808, 1995

30 Bhakdi S, "Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation" 19 : 2348-2354, 1999

31 Craswell PW, "Chronic renal failure with gout: a marker of chronic lead poisoning" 26 : 319-323, 1984

32 Hayashi T, "An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells" 79 : 2930-2936, 1992

33 Sautin YY, "Adverse effects of the classic antioxidant uric acid in adipocytes:NADPH oxidase-mediated oxidative/nitrosative stress" 293 : C584-C596, 2007

34 Levey AS, "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group" 130 : 461-470, 1999

35 Frosst P, "A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase" 10 : 111-113, 1995